Dec 16 (Reuters) - Shanghai Fosun Pharmaceutical Group
said on Wednesday that BioNTech SE agreed
to supply 100 million doses of its COVID-19 vaccine, if
approved, to mainland China next year.
Pfizer and BioNTech's COVID-19 vaccine has already received
approval for emergency use in several countries, including the
U.S., UK, and Singapore.
(Reporting by Nikhil Kurian Nainan in Bengaluru
Editing by Shri Navaratnam)